1. Home
  2. Analysis
  3. Telmisartan
  4. Pulmonary-toxicity

Telmisartan and Pulmonary toxicity - a phase IV clinical study of FDA data

Summary:

Pulmonary toxicity is reported as a side effect among people who take Telmisartan (telmisartan), especially for people who are male, 60+ old, also take Simponi, and have Hyperuricaemia.

The phase IV clinical study analyzes which people have Pulmonary toxicity when taking Telmisartan. It is created by eHealthMe based on reports of 8,644 people who have side effects when taking Telmisartan from the FDA, and is updated regularly.

What is Telmisartan?

Telmisartan has active ingredients of telmisartan. It is often used in high blood pressure. eHealthMe is studying from 9,163 Telmisartan users. Check the latest studies of Telmisartan.

What is Pulmonary toxicity?

Pulmonary toxicity (side effects on the lungs) is found to be associated with 375 drugs and 468 conditions by eHealthMe. Check the latest studies of Pulmonary toxicity.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

8,644 people reported to have side effects when taking Telmisartan.
Among them, 16 people (0.19%) have Pulmonary toxicity.

Could Telmisartan cause Pulmonary toxicity?

Among these 16 people:

What is the gender of people who have Pulmonary toxicity when taking Telmisartan? *

  • female: 50 %
  • male: 50 %

What is the age of people who have Pulmonary toxicity when taking Telmisartan? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 50 %
  • 60+: 50 %

What are other drugs people take besides Telmisartan? *

  1. Sulfasalazine: 6 people, 37.50%
  2. Simponi: 6 people, 37.50%
  3. Apixaban: 5 people, 31.25%
  4. Empagliflozin: 5 people, 31.25%
  5. Rinvoq: 5 people, 31.25%
  6. Magnesium Citrate: 5 people, 31.25%
  7. Metformin Hydrochloride: 5 people, 31.25%
  8. Methotrexate: 4 people, 25.00%
  9. Vitamin D: 3 people, 18.75%
  10. Pantoprazole: 3 people, 18.75%

What are other side effects people have besides Pulmonary toxicity? *

  1. Drug Ineffective: 7 people, 43.75%
  2. Osteoarthritis (a joint disease caused by cartilage loss in a joint): 5 people, 31.25%
  3. Trigger Finger: 5 people, 31.25%
  4. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 31.25%
  5. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 5 people, 31.25%
  6. Diabetes: 5 people, 31.25%
  7. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 5 people, 31.25%
  8. Prostatic Specific Antigen Abnormal: 5 people, 31.25%
  9. Umbilical Hernia (an outward bulging (protrusion) of the abdominal lining or part of the abdominal organ(s) through the area around the belly button): 5 people, 31.25%
  10. Interstitial Lung Disease: 3 people, 18.75%

What are the existing conditions these people have? *

  1. Hyperuricaemia (level of uric acid in the blood that is abnormally high): 3 people, 18.75%
  2. Rashes (redness): 2 people, 12.50%
  3. Metastatic Carcinoma Of The Bladder (cancer types can spread to the bladder from other place): 2 people, 12.50%
  4. Lung Cancer - Non-Small Cell (lung cancer): 2 people, 12.50%
  5. Urination - Excessive Volume: 1 person, 6.25%
  6. Infection: 1 person, 6.25%
  7. Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 1 person, 6.25%
  8. Connective Tissue Disorder (any disease that has the connective tissues of the body): 1 person, 6.25%
  9. Dehydration (dryness resulting from the removal of water): 1 person, 6.25%
  10. Folliculitis (infection of hair root): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Telmisartan and have Pulmonary toxicity?

- Check whether Pulmonary toxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Telmisartan:

Pulmonary toxicity treatments and more:

How severe was Pulmonary toxicity and when was it recovered:

Expand to all the drugs that have ingredients of telmisartan:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Telmisartan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pulmonary toxicity:

Browse all the conditions that are associated with Pulmonary toxicity:

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on telmisartan (the active ingredients of Telmisartan) and Telmisartan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.